Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S Advani, MD, Madeline Waldron, PharmD, BCOP, Caitlin Siebenaller, PharmD, Jenna Thomas, Eric Parsons, RN, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139515

Published: 2020

Journal Articles

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Agrima Mian, MBBS, MD, Wei Wei, MS, Brian T. Hill, MD, Betty K. Hamilton, MD, Allison M. Winter, MD, Jack Khouri, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Faiz Anwer, MD, Aaron T. Gerds, MDMS, Matt Kalaycio, MD, Robert M. Dean, MD, Ronald Sobecks, MD, Navneet S. Majhail, MD MS

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-137801

Published: 2020

Journal Articles

Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Sanghee Hong, MD, Lisa Rybicki, MS, Linda McLellan, LISW, Jane Dabney, LISW-S, Aaron T. Gerds, MDMS, Seth J Rotz, MD, Matt Kalaycio, MD, Rabi Hanna, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Ronald Sobecks, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-138939

Published: 2020

Journal Articles

Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Nathan Radakovich, BA, Luca Malcovati, MD, Manja Meggendorfer, PhD, Mikkael A. Sekeres, MD MS, Jacob Shreve, MD MS, Cameron Beau Hilton, MD, Yazan Rouphail, Wencke Walter, PhD, Stephan Hutter, PhD, Anna Gallì, Sarah Pozzi, Aaron T. Gerds, MDMS, Sudipto Mukherjee, MD PhD MPH, Cassandra M Kerr, MS, Babal K. Jha, PhD, Claudia Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Torsten Haferlach, MD, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140023

Published: 2020

Journal Articles

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Kimberly C Jenkins, MSNM, Emily C Zabor, DrPH, Lindsey A. R. Mooney, BS, Aaron T. Gerds, MDMS, Kerry O'Hop, BS, Makenzie Guy, BA, Megan Kilbane, MBA, Nathan A Pennell, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139937

Published: 2020

Journal Articles

Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Naveen Pemmaraju, MD, Aaron T. Gerds, MDMS, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, MD PhD, Anne Shah, Ann Xi, PharmD, Shambhavi Kumar, MS, Robyn M. Scherber, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-141370

Published: 2020

Journal Articles

Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib

Jonathan K. Kish, PhD MPH, Arianna Kee, Pranav Abraham, Ronda Copher, PhD, Talia Miller, Aaron T. Gerds, MDMS

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-136656

Published: 2020

Journal Articles

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

John Mascarenhas, MD, Heidi E. Kosiorek, MS, Lilian Varricchio, PhD, Rupali Bhave, MD, Andrew T. Kuykendall, MD, Rami Komrokji, MD, Aaron T. Gerds, MDMS, Jeanne M. Palmer, MD, Amelia R. Gabler, Lonette Sandy, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, PhD, Paul I. Nadler, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-140830

Published: 2020

Journal Articles

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Siddharth Jayant Kunte, MD, Lisa Rybicki, MS, Auro Viswabandya, MD, Asad Bashey, MD PhD, Madiha Iqbal, MBBS, Michael R. Grunwald, MD, Bhagirathbhai Dholaria, MBBS, Hany Elmariah, MDMS, Michael Ozga, MD, Anurag K. Singh, MD, Sameem Abedin, MD, Vikas Gupta, MD FRCP, FRCPath, Amy E. DeZern, MD, Richard J. Jones, MD, Aaron T. Gerds, MDMS, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136622

Published: 2020

Journal Articles

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-137265

Published: 2020

Journal Articles

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Francesco Passamonti, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Brian Higgins, Ling-Yuh Huw, PhD, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD, John Mascarenhas, MD

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-136135

Published: 2020

Journal Articles

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-139412

Published: 2020

Journal Articles

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

John Mascarenhas, MD, Brian Higgins, Doreen Anders, Kate Burbury, MD, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Bruno Kovic, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD

Blood (2020) 136 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2020-135868

Published: 2020

Journal Articles

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Eric Parsons, RN, Jenna Thomas, Hetty E. Carraway, MD MBA, Dale Grabowski, BS, Yihong Guan, PhD, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Anjali S Advani, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139494

Published: 2020

Journal Articles

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Naveen Pemmaraju, MD, Aaron T. Gerds, MDMS, Jingbo Yu, MD PhD, Shreekant Parasuraman, BPharm, PhD, Anne Shah, Ann Xi, PharmD, Shambhavi Kumar, MS, Robyn M. Scherber, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-141333

Published: 2020

Journal Articles

Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States

Raffi Tchekmedyian, BS, Tomas Radivoyevitch, PhD, Aaron T. Gerds, MDMS, Aziz Nazha, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Jaroslaw P. Maciejewski, Matt Kalaycio, MD, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MDPhDMPH

Blood (2018) 132 (Supplement 1): 371.

https://doi.org/10.1182/blood-2018-99-119661

Published: 2018

Journal Articles

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Naval G. Daver, MD, Marina Kremyanskaya, MD PhD, Casey O'Connell, MD, Kim-Hien Dao, DO,PhD, Stephen T Oh, MD PhD, Aaron T. Gerds, MDMS, Srdan Verstovsek, MD PhD, Sue Erickson-Viitanen, PhD, Feng Zhou, Albert Assad, MD, Abdulraheem Yacoub, MD

Blood (2018) 132 (Supplement 1): 353.

https://doi.org/10.1182/blood-2018-99-111338

Published: 2018

Journal Articles

Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety

Madeline Waldron, PharmD, Caitlin Siebenaller, PharmD, Marc Earl, PharmD, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MDMS, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Barb Tripp, CNS, Brian P. Hobbs, PhD, Sudipto Mukherjee, MD PhD MPH, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 712.

https://doi.org/10.1182/blood-2018-99-110029

Published: 2018

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

NARROW

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only